Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex® Quattro)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
▴ This novel ultra-short-course seasonal allergy vaccine, containing glutaraldehyde-modified allergens and the adjuvants 3-deacylated monophosphoryl lipid A (MPL®) and L-tyrosine, requires a preseasonal course of only four injections to be effective in the treatment of seasonal allergic rhinitis.
▴ In patients with seasonal allergic rhinitis and/or allergic asthma, a four-injection vaccination course with either the grass pollen or tree pollen allergy vaccine significantly reduced skin prick sensitivity reactions, significantly elevated allergen-specific IgG levels and significantly reduced the seasonally induced boost of IgE.
▴ Preseasonal vaccination of adult patients with either grass pollen or tree pollen allergy vaccine significantly reduced the median combined symptom/ medication score compared with placebo.
▴ Similarly, preseasonal vaccination of children and adolescents with allergies to grass pollen or tree pollen significantly reduced the global symptom and medication use scores compared with the previous pollen season.
▴ Postmarketing surveillance indicated that after a course of vaccination, 82% of patients experienced reduced symptoms and 62% reduced their rescue medication use compared with the previous season.
▴ The allergy vaccine was generally well tolerated. Local reactions, mainly injection-site redness and swelling, were more common than systemic reactions. There were no serious adverse events.
- van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000 Feb; 55(2): 116–34 CrossRef
- Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000 Jan; 17(1): 37–52 CrossRef
- Plaut M, Valentine MD. Allergic rhinitis. N Engl J Med 2005 Nov 3; 353(18): 1934–44 CrossRef
- Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002 Feb; 109(2): 251–6 CrossRef
- Hellman L, Carlsson M. Allergy vaccines: a review of developments. Clin Immunother 1996 Aug; 6: 130–42 CrossRef
- Wheeler AW, Woroniecki SR. Allergy vaccines: new approaches to an old concept. Expert Opin Biol Ther 2004; 4(9): 1473–81 CrossRef
- Till SJ, Francis JN, Nouri-Aria K, et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004 Jun; 113(6): 1025–34 CrossRef
- Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005 Nov; 116(5): 961–8 CrossRef
- Baldrick P, Richardson D, Wheeler AW, et al. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy. J Appl Toxicol 2004 Aug; 24(4): 261–8 CrossRef
- Clay M, Urban E. Specific immunotherapy using pollen aller-goids adjuvanted with monophosphoryl lipid A over a three year period shows good efficacy and increased tolerability [abstract no. 4]. Clin Exp Allergy 2005; 35: 1411. Plus poster presented at the Annual Conference of the British Society for Allergy and Clinical Immunology; 2005 Jul 18–21; Loughborough, UK
- Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001 Oct; 126(2): 135–9 CrossRef
- Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003 Sep; 33(9): 1198–208 CrossRef
- Baldrick P, Richardson D, Wheeler AW. Review of L-tyrosine confirming its safe human use as an adjuvant. J Appl Toxicol 2002; 22: 333–44 CrossRef
- Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001 Jun; 56: 498–505 CrossRef
- Drachenberg KJ, Heinzkill M, Urban E. Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid A: results from a multicentre, placebocontrolled, randomised, double-blind study [in German]. Al-lergologie 2002; 25(9): 466–74
- Röver AC, Reimann S, Zuberbier T, et al. Immunophenotypic characterization of peripheral B cells during short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. J Invest Allergol Clin Immunol 2002; 12(4): 227–34
- Drachenberg KJ, Heinzkill M, Urban E, et al. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL®) for children and adolescents. Allergol et Immunopathol 2003; 31(5): 270–7 CrossRef
- Stuck BA, Schneider-Gene S, Schäfer D, et al. Short-term preseasonal immunotherapy with birch pollen allergoid plus monophosphoryl lipid A (MPL): influence of cytokine production of peripheral T cells in patients with allergic rhinitis. Allergy Clin Immunol Int - J World Allergy Org 2004; 16(2): 60–4 CrossRef
- von Baehr V, Hermes A, von Baehr R, et al. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Thl-adjuvanted allergy vaccine. J Investig Allergol Clin Immunol 2005; 15(4): 234–41
- Drachenberg KJ, Pröll S, Urban E, et al. Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: a post-marketing surveillance study. Int Rev Allergol Clin Immunol 2002; 8(4): 219–23
- Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999 Aug 12; 341(7): 468–75 CrossRef
- Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex® Quattro)
Volume 66, Issue 7 , pp 931-938
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors